Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.51
−$0.05 · -1.95%
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Regular session
$2.51
−$0.05 · -1.95%
Regular session · ET · Market data may be delayed.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Day range
Current $2.51
52-week range
Current $2.51
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
65
Bullish
Risk
66
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Day range
Current $2.51
52-week range
Current $2.51
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 13K USD | — | — | — | 1.12M USD |
| Gross profit | −13K USD | — | — | — | −1.12M USD |
| Research and development | 30.75M USD | 12.34M USD | 11.71M USD | 11.76M USD | 119.62M USD |
| Selling, general, and administrative | 15.39M USD | 42.92M USD | 1.76M USD | 2.24M USD | 49.08M USD |
| Operating expenses | 46.14M USD | 55.26M USD | 13.46M USD | 14.01M USD | 168.7M USD |
| Interest income | — | 5.49M USD | — | — | 1.32M USD |
| Interest expense | 1.44M USD | — | 687K USD | 235K USD | — |
| Depreciation and amortization | 13K USD | — | — | — | 1.12M USD |
| Operating income | −46.15M USD | −55.26M USD | −13.46M USD | −14.01M USD | −169.82M USD |
| Net income | −43.44M USD | −58.77M USD | −14.7M USD | −15.49M USD | −171.96M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 16, 2025 | 1:23 | — | — |
Effective Jan 16, 2025
1:23
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.03M0.00%2.3T USD0.03%$379.58-0.38%
Vanguard Extended Market ETFVXF554.99K0.00%95.4B USD0.05%$231.46-0.87%
iShares Micro-Cap ETFIWC73.72K0.01%1.33B USD0.60%$181.07-1.25%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM60K0.05%116.75M USD0.73%$15.77-1.25%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR8.77K0.00%45.43B USD0.17%$83.84-0.31%
U.S. Vector Equity Portfolio ETF Class SharesDXUV7.32K0.00%6.16B USD0.26%$67.735-0.33%
Dimensional - US Core Equity 2 ETFDFAC6.95K0.00%88.28B USD0.21%$45.00-0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
